GSK Wagers On Cervarix In Head-To-Head Trial Against Gardasil
This article was originally published in The Pink Sheet Daily
Executive Summary
Trial will be the first to directly compare sustained immune response in women treated with the two cervical cancer vaccines.
You may also be interested in...
Biogen Idec/Elan Plan To Appeal Negative CHMP Opinion Of Tysabri For Crohn’s
Committee also issues positive opinions on Novartis’ type 2 diabetes therapy Galvus, Pfizer’s oral HIV treatment Celsentri and GSK’s cervical cancer vaccine Cervarix.
Biogen Idec/Elan Plan To Appeal Negative CHMP Opinion Of Tysabri For Crohn’s
Committee also issues positive opinions on Novartis’ type 2 diabetes therapy Galvus, Pfizer’s oral HIV treatment Celsentri and GSK’s cervical cancer vaccine Cervarix.
Merck Seeks Additional Claims For Gardasil
sBLA includes data showing protection against two additional gynecological cancers.